Clinical Trials
0
0 active
Approvals
168
Total approvals
Agencies
4
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
- Arbitration tribunal ruled in favor of Servier, reaffirming Allogene's full development and commercial control of cemacabtagene ansegedleucel (cema-cel) in the US, EU, and UK markets. - The decision rejected Cellectis's breach allegations and financial claims, with milestone payments only due upon FDA acceptance of a Biologics License Application. - Allogene approaches a critical 1H 2026 interim futility analysis for its pivotal Phase 2 ALPHA3 trial testing cema-cel in first-line large B-cell lymphoma consolidation.
• Novo Nordisk's liraglutide demonstrated a significant reduction in BMI in a Phase III trial involving children aged 6-11, showing potential for pediatric obesity treatment. • Vaxcyte's VAX-31 pneumonia vaccine showed positive Phase I/II topline data, increasing its Phase Transition Success Rate (PTSR) in streptococcal pneumonia. • Pfizer terminated a Phase I trial of maplirpacept, leading to a decrease in its PTSR for peripheral T cell lymphoma and B cell Hodgkin lymphoma. • Les Laboratoires Servier's oncology drug trial was terminated due to business reasons, impacting the PTSR of S-64315 and S-65487 in multiple myeloma and leukemia.
